| | | | | nearly $2 billion market. In addition, the complications |
| Global Drug Eluting Balloons (DEB) Pipeline Analysis, | | | | associated with long term antiplatelet therapy such as |
| Opportunity Assessment and Market Forecasts to | | | | the risk of bleeding and contraindications limit the use |
| 2016 | | | | of the current interventions. Also, the associated cost |
| The report provides key data, information and | | | | and patient compliance for current treatments open |
| analysis on the global Drug Eluting Balloons (DEB) | | | | the door for drug eluting balloons to these markets. |
| market. The report provides market landscape, | | | | The unique value proposition of drug eluting balloons |
| competitive landscape and market trends information | | | | – by improving both the safety and efficacy for |
| the Drug Eluting Balloons (DEB) market. The report | | | | some indications – has the potential to create a |
| provides comprehensive information on the key | | | | niche market for DEBs. Preliminary clinical trial results |
| trends affecting the market, and key analytical | | | | suggest that DEBs could become the standard |
| content on the market dynamics. The report also | | | | treatment for peripheral vascular disease and |
| reviews the competitive landscape, key pipeline | | | | complex lesions in the future. For instance, |
| products and technology offerings. ( ) | | | | PACCOCATH ISR I and II show significant reductions |
| The Global Drug Eluting Balloons Market Is Expected | | | | in binary restenosis as compared to balloon |
| To Nearly Double Over the Next Seven Years | | | | angioplasty. Another study showing the efficacy of |
| The global Drug Eluting Balloons (DEBs) market was | | | | DEB for Small Vessel Disease (SVD) showed a binary |
| valued at $60m in 2009 and is expected to grow at | | | | restenosis rate of just 5.5%. Market experts |
| 10% over the next seven years. The market will be | | | | estimate that DEBs will account for more than 90% |
| driven by increased adoption by physicians as long | | | | of all percutaneous interventions for peripheral vessel |
| term clinical data is released, and as the device is | | | | diseases in the future. |
| adopted for newer indications such as peripheral | | | | B Braun, Eurocor and Invatec Dominate Global Drug |
| vascular disease. Food and Drug Administration (FDA) | | | | Eluting Balloons Market |
| product approvals over the next two to three years | | | | B Braun, Eurocor and Invatec are the three leading |
| are also expected to boost uptake in the future, | | | | companies in the drug eluting balloons market and |
| since the US is a major interventional cardiology | | | | together account for nearly 96% of the total |
| device market. Moreover, since drug eluting balloons | | | | market. B Braun is the market leader with a 60% |
| fulfill a huge unmet need gap in the market, the | | | | market share, followed by Eurocor and Invatec with |
| adoption is bound to increase as more physicians | | | | 30% and 6% share respectively. B Braun's product |
| become aware of the product. | | | | SeQuent Please currently has the largest number of |
| Drug Eluting Balloon's Potential to Become a Viable | | | | completed and ongoing clinical trials. Bayer's |
| Treatment for a Large Number of Indications to | | | | PACCOCATH technology has also been successfully |
| Drive the Market | | | | demonstrated in animal models. Although Invatec has |
| Small vessel disease, bifurcated lesions, in-stent | | | | three approved products, it entered the market only |
| restenosis and peripheral vascular disease represent a | | | | in 2009. |